Companies: 10,795·Total market cap: $144.5T
Insmed Incorporated

Insmed Incorporated

INSMNASDAQHealthcare● Active
$94.00
$-0.22(-0.23%)
Market Cap$20.4B
P/E Ratio
52W High$212.75
52W Low$70.57

Insmed Incorporated (INSM) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

insm · stock forecast · 35 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 35 Wall Street analysts in the past 3 months

SellBuy

Buy

35 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
33
Hold
1
Sell
1
Strong Sell
0
Total: 35 · Buy rate: 94.3%

12-Month Price Target

High

$269

Consensus

$210

+123.1% upside

Low

$160

Median: $212 · Last Close: $94.22

The Insmed Incorporated (INSM) analyst consensus is Buy, based on ratings from 35 Wall Street analysts over the past 3 months. The average 12-month INSM price target is $210.18, representing +123.1% upside from the current price of $94.22.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $210 (123.1%)

Consensus Target

$210.18

123.1% upside

High Target

$269

185.5%

Low Target

$160

69.8%

Current Price

$94.22

as of today

Based on analyst price targets, the INSM stock price prediction for the next 12 months ranges from $160 to $269. The consensus INSM price forecast of $210.18 implies 123.1% upside from the current price of $94.22.

Short-Term Price Prediction

Bear

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$91.023.40%

1-day model range: $89.8–$92.23. Peak: $92.23 (-3.40%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$138+46.5%
2028$180+90.8%
2029$215+128.3%
2030$243+157.5%
2031+178.8%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

7%0%93%
1Buy
0Neutral
13Sell
RSI (14)26.1Oversold
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · INSM · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$102.55SELL
MA 10$104.96SELL
MA 20$107.28SELL
MA 50$130.54SELL
MA 100$140.78SELL
MA 200$155.28SELL
Current $INSM · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$101.51SELL
EMA 10$104.41SELL
EMA 20$109.96SELL
EMA 50$124.03SELL
EMA 100$136.19SELL
EMA 200$138.18SELL
Current $INSM · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
RBC Capital2026-06-05
Maintains
OutperformOutperform
Truist Securities2026-05-14
Maintains
BuyBuy
Wells Fargo2026-05-08
Maintains
OverweightOverweight
RBC Capital2026-05-08
Maintains
OutperformOutperform
Guggenheim2026-05-08
Maintains
BuyBuy
Roth Capital2026-04-17
Maintains
BuyBuy
RBC Capital2026-04-14
Maintains
OutperformOutperform
Barclays2026-04-01
Maintains
OverweightOverweight
Morgan Stanley2026-03-30
Upgrade ↑
Equal WeightOverweight
HC Wainwright & Co.2026-03-26
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Insmed Incorporated (INSM) stock. Of the recent 205 rating actions, 5 were upgrades and 4 were downgrades. 35 analysts currently cover INSM.

Analyst Recommendation Trends

Buy ratings211
Hold ratings101
Sell ratings00

INSM analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$1.7B

↓ 56.1% YoY

Revenue Next Year

$2.8B

↑ 64.8% YoY

EPS This Year

$-2.79

EPS Next Year

$0.49

↓ 117.6% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast INSM EPS of $-2.79 for the current fiscal year, based on estimates from 15 analysts. The INSM revenue forecast is $1.7B for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The INSM stock forecast is supported by two independent data sources: analyst consensus ratings from 35 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus INSM price target is $210.18 (+123.1% upside), with an analyst consensus of Buy.

The INSM short-term stock prediction for tomorrow is $91.02 (-3.40%). The INSM stock price prediction for 2027 estimates an average of $138. The INSM stock prediction for 2030 projects a range of $215–$270.

Insmed Incorporated trades on NASDAQ under the ticker INSM. The INSM stock outlook for 2027 is broadly positive, supported by a Buy consensus among 94% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

INSM forecast · 8 questions

According to 35 Wall Street analysts, the average 12-month INSM price target is $210.18, with a high forecast of $269.00 and a low of $160.00. The median price target is shown in the chart above when available. This implies +123.1% potential upside from the current price of $94.22.

INSM price targetWhat is INSM price targetINSM analyst price targetINSM 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.